Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Study: Nearly 60 Percent of Employees with Access to a Company Wellness Program Say the Initiative Has Made a Positive Impact on Their Health

Most employees with access to workplace wellness programs say they have made a positive impact on their health, even though a majority are unwilling to devote more than one hour per day to health-related activities such as consistent exercise, according to a new survey.

Read More »

Aeolus Announces FDA Fast Track Designation Granted to AEOL 10150 for Treatment of Patients With Lung Acute Radiation Syndrome Following a Radiologial or Nuclear Event

Aeolus Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration granted Fast Track designation to AEOL 10150 for the prevention of fatal respiratory failure among patients at risk for radiation pneumonitis following a radiological/nuclear incident sufficient to cause the Acute Radiation Syndrome.

Read More »

Mobile Healthcare Marketing: How Your Phone’s Camera Will Change Medical Marketing

Pharma has been slow – painfully slow – to adopt mobile marketing strategies and tactics.

Read More »

Teva’s migraine drug clears another hurdle

Teva Pharmaceutical Industries Ltd. said its experimental drug to prevent migraines cleared another late-stage study.

Read More »

Novartis touts new T-cell therapy data in race for FDA approval

Novartis touted new data from its T-cell therapy CTL019, saying it is on a par with results of experimental molecules from Kite Pharma and Juno Therapeutics that also target aggressive blood cancers.

Read More »

AbbVie’s RA drug succeeds in late-stage trial

AbbVie’s rheumatoid arthritis drug was superior to a placebo in a late-stage study involving patients that have not responded adequately to standard treatments.

Read More »

Blood and bone marrow therapies grab spotlight at world’s top cancer meeting

Promising new data on blood and bone marrow cancer therapies that re-engineer immune system cells are convincing more doctors of the validity of the approach, according to Reuters interviews at the world’s biggest annual oncology meeting.

Read More »

Bristol-Myers Squibb Loses $4.3 Billion in Market Value After ASCO Update

In the eyes of investors, Bristol-Myers Squibb has not really recovered from bad news in August 2016 of its clinical trial of Opdivo (nivolumab) as monotherapy in non-small cell lung cancer. Although the company had quite a bit of good news at the June 2017 ASCO meeting, investors still seem leery.

Read More »

Hundreds of Patient Deaths Linked to Roche’s RA Drug Actemra

Roche’s seven-year-old rheumatoid arthritis drug Actemra is being linked to hundreds of deaths due to undisclosed side effects.

Read More »

AstraZeneca sells migraine drug for up to $302 million

AstraZeneca continued its program of divesting old medicines with the sale for up to $302 million of migraine drug Zomig to Germany’s Grunenthal.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!


Ad Right Bottom